Intercellular Signaling Peptides and Proteins
- Intercellular Signaling Peptides and Proteins
- Accession Number
Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.
Drug Drug Description Denileukin diftitox A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Peginterferon alfa-2a A modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses. Interferon alfa-n1 A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Darbepoetin alfa A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Erythropoietin A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Interferon alfa-n3 A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Pegfilgrastim A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. Sargramostim A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. Peginterferon alfa-2b A purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers. Anakinra A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. Interferon gamma-1b A form of recombinant human interferon used to treat infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis. Oprelvekin A form of recombinant interleukin-11 used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy. Palifermin A form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy. Aldesleukin A recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma. Interferon beta-1a A form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis. Interferon beta-1b A form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms. Interferon alfacon-1 A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections. Becaplermin A recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area. Mecasermin A recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH. Abaloparatide A parathyroid hormone-related protein (PTHrP) analog used for the treatment of osteoporosis in postmenopausal women with a high risk of fracture. Leptin Investigated for use/treatment in lipodystrophy and obesity. Interferon alfa Investigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma. Cintredekin besudotox Investigated for use/treatment in brain cancer. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Ciliary neurotrophic factor Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified). Albinterferon Alfa-2B Investigated for use/treatment in hepatitis (viral, C). Fibroblast growth factor-1 Investigated for use/treatment in coronary artery disease and peripheral vascular disease. IRX-2 Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors. Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. CTCE-0214 Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases. IRL-1620 Investigated for use/treatment in cancer/tumors (unspecified). Icatibant A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE). Trafermin Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers. Endostatin Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy. Repifermin Investigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease. Velafermin Investigated for use/treatment in adverse effects (chemotherapy). Thrombopoietin Investigated for use/treatment in thrombocytopenia. Labradimil Investigated for use/treatment in brain cancer and pediatric indications. Emfilermin Investigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility. Metreleptin A leptin analogue used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Ancestim A human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection. Methoxy polyethylene glycol-epoetin beta A synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease. Peginterferon beta-1a An interferon beta used to treat relapsing forms of multiple sclerosis. Epoetin delta Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo. Eptotermin alfa A bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis. Eptotermin alfa is an ingredient in... Dibotermin alfa indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. indicated for single-level... Avotermin Juvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix. TAK-448 TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism. Interleukin-7 Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer. Nagrestipen Nagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis. Bradykinin Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2. Binetrakin Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others. Dulanermin Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. Muplestim Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in... Molgramostim Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis. Sprifermin Sprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee. Nerve Growth Factor Nerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others. Endothelin-1 Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin). Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Interleukin-10 Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others. Lenograstim A granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors. Lipegfilgrastim A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. Interleukin-1 alpha, human recombinant Not Annotated Basic Fibroblast Growth Factor Basic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications. Nepidermin Not Annotated Insulin-like growth factor II The insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth... Regramostim Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant. Sar9, Met (O2)11-Substance P Investigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection. Peginterferon lambda-1a Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C). Human interleukin-2 Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL). Human interferon beta A polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS). Recombinant CD40-ligand Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma). Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Interferon alfa-2c Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma). ALT-801 ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia). Tucotuzumab celmoleukin Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous... Lorukafusp alfa Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma). Endostar Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. Bempegaldesleukin Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib... Pegilodecakin Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer). Pegbelfermin Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis). Edodekin alfa Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or... Viral Macrophage-Inflammatory Protein Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer... Interferon Kappa Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it... Kisspeptin-10 Kisspeptin-10 is under investigation in clinical trial NCT03771326 (KP-10 and Insulin Secretion in Men). Parathyroid Hormone-Related Protein 1-36 Parathyroid Hormone-Related Protein 1-36 is under investigation in clinical trial NCT00853723 (Comparison Study of Pthrp and PTH to Treat Osteoporosis). Tengonermin Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
- Drugs & Drug Targets